Post-Remission Treatment With Chemotherapy Or Allogeneic Hematopoietic Stem Cell Transplantation (Allohsct) In Adult Patients With High-Risk (Hr) Philadelphia Chromosome-Negative (Ph-Neg) Acute Lymphoblastic Leukemia (All) According To Their Minimal Residual Disease (Mrd). Final Results Of The Pethema All-Hr-11 Trial

Introduction: Recent studies have shown that young to middle-aged adults who receive a pediatric-inspired chemotherapy regimen for treatment of Ph-neg ALL do not appear to require an alloHSCT if they achieve good response on MRD testing after induction and/or consolidation therapy. Patients (pts) who are not good MRD responders achieve better outcomes with alloHSCT than their counterparts who do not receive alloHSCT. However, it is not clear if this approach can specifically apply to adult ALL pts with HR features at baseline. The aim of the prospective ALL-HR-11 trial (NCT01540812) from the Spanish PETHEMA Group was to evaluate response of HR Ph-neg adult ALL patients to a different post-induction therapy (chemotherapy or alloHSCT) according to MRD levels (centrally assessed by 8-color flow cytometry [FCM]) at the end of induction (week 5) and consolidation therapy (week 17)..